- Home
- ANET vs VRTX Comparison
ANET vs VRTX Comparison
Compare ANET & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANET
- VRTX
- Stock Information
- Founded
- ANET 2004
- VRTX 1989
- Country
- ANET United States
- VRTX United States
- Employees
- ANET N/A
- VRTX N/A
- Industry
- ANET Computer Communications Equipment
- VRTX EDP Services
- Sector
- ANET Telecommunications
- VRTX Technology
- Exchange
- ANET Nasdaq
- VRTX Nasdaq
- Market Cap
- ANET 119.2B
- VRTX 128.5B
- IPO Year
- ANET 2014
- VRTX 1991
- Fundamental
- Price
- ANET $401.78
- VRTX $450.56
- Analyst Decision
- ANET Buy
- VRTX Buy
- Analyst Count
- ANET 20
- VRTX 29
- Target Price
- ANET $385.67
- VRTX $513.58
- AVG Volume (30 Days)
- ANET 2.3M
- VRTX 1.3M
- Earning Date
- ANET 11-07-2024
- VRTX 11-04-2024
- Dividend Yield
- ANET N/A
- VRTX N/A
- EPS Growth
- ANET 38.55
- VRTX N/A
- EPS
- ANET 8.33
- VRTX N/A
- Revenue
- ANET $6,613,147,000.00
- VRTX $10,625,800,000.00
- Revenue This Year
- ANET $19.25
- VRTX $12.20
- Revenue Next Year
- ANET $18.53
- VRTX $8.31
- P/E Ratio
- ANET $45.83
- VRTX N/A
- Revenue Growth
- ANET 18.19
- VRTX 10.06
- 52 Week Low
- ANET $210.69
- VRTX $346.29
- 52 Week High
- ANET $431.97
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- ANET 52.26
- VRTX 36.95
- Support Level
- ANET $368.40
- VRTX $489.02
- Resistance Level
- ANET $403.77
- VRTX $519.88
- Average True Range (ATR)
- ANET 11.13
- VRTX 15.24
- MACD
- ANET -2.33
- VRTX -5.61
- Stochastic Oscillator
- ANET 43.81
- VRTX 3.95
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.